Literature DB >> 34936754

Lutetium-177-PSMA-617 for Prostate Cancer. Reply.

Oliver Sartor1, Michael J Morris2, Bernd J Kraus3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34936754     DOI： 10.1056/NEJMc2116647

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

Review 1.  The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer.

Authors:  Yishen Wang; Joao R Galante; Athar Haroon; Simon Wan; Asim Afaq; Heather Payne; Jamshed Bomanji; Sola Adeleke; Veeru Kasivisvanathan
Journal:  Nat Rev Urol       Date:  2022-07-04       Impact factor: 16.430

2.  89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man.

Authors:  Bastiaan M Privé; Yvonne H W Derks; Florian Rosar; Gerben M Franssen; Steffie M B Peters; Fadi Khreish; Mark Bartholomä; Stephan Maus; Martin Gotthardt; Peter Laverman; Mark W Konijnenberg; Samer Ezziddin; James Nagarajah; Sandra Heskamp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-12-21       Impact factor: 10.057

3.  177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).

Authors:  Fadi Khreish; Zaidoon Ghazal; Robert J Marlowe; Florian Rosar; Amir Sabet; Stephan Maus; Johannes Linxweiler; Mark Bartholomä; Samer Ezziddin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-09-07       Impact factor: 9.236
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.